The non-competitive NMDA receptor blocker dizocilpine potentiates serotonergic function

Area of Science:

• Neuroscience
• Pharmacology

Background:

• Serotonin (5HT) and glutamate systems interact in the brain.
• N-methyl-D-aspartate (NMDA) receptors are key glutamate receptors.
• Dysregulation of these systems is implicated in psychiatric disorders like schizophrenia.

Purpose of the Study:

• To investigate the differential effects of competitive and non-competitive NMDA receptor antagonists on serotonin-mediated behaviors in rats.
• To explore the role of NMDA receptor antagonism in modulating serotonergic and dopaminergic activity.

Main Methods:

• Rats were pretreated with NMDA antagonists (dizocilpine, CGP 43487) before administration of serotonin agonists (8-OH-DPAT, DOI, (-)5HTP) or induction of locomotor activity.
• Subsequent administration of serotonin receptor antagonists (ketanserin) and dopamine receptor blockers (SCH 23390, (-)sulpiride) was used to probe receptor interactions.

Main Results:

• Non-competitive NMDA antagonist dizocilpine significantly potentiated forepaw treading, head shakes, and locomotor activity induced by serotonin agonists.
• Competitive NMDA antagonist CGP 43487 only enhanced DOI-induced head shakes.
• Dopamine receptor antagonists blocked dizocilpine's facilitation of locomotion and forepaw treading, but not head shakes.

Conclusions:

• Non-competitive NMDA receptor antagonists enhance serotonergic neurotransmission, whereas competitive antagonists do not.
• These findings suggest that glutamate deficiency may contribute to schizophrenia pathogenesis via serotonergic hyperactivity.
• The results highlight distinct roles for NMDA receptor antagonism in modulating neurotransmitter systems relevant to psychiatric disorders.